Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.63 HKD | 0.00% | +10.53% | 0.00% |
Apr. 23 | Kingworld Medicines Posts 68% Jump in 2023 Profit | MT |
Mar. 27 | Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 535.7 | 489.6 | 392.9 | 385.5 | 467.3 | 356.5 |
Enterprise Value (EV) 1 | 696.6 | 592.5 | 437.3 | 426 | 501.8 | 516.8 |
P/E ratio | 13.1 x | 11.2 x | 33.1 x | 12.4 x | 20 x | 8.89 x |
Yield | 2.3% | 2.66% | 0.87% | 3.15% | 2.9% | 5.34% |
Capitalization / Revenue | 0.5 x | 0.5 x | 0.53 x | 0.45 x | 0.49 x | 0.33 x |
EV / Revenue | 0.65 x | 0.61 x | 0.59 x | 0.5 x | 0.52 x | 0.48 x |
EV / EBITDA | 7.68 x | 6.29 x | 4.8 x | 4.42 x | 4.67 x | 5.84 x |
EV / FCF | 13.2 x | 5.34 x | 4.09 x | 39.9 x | 5.74 x | -7.96 x |
FCF Yield | 7.56% | 18.7% | 24.5% | 2.5% | 17.4% | -12.6% |
Price to Book | 0.95 x | 0.81 x | 0.66 x | 0.62 x | 0.76 x | 0.55 x |
Nbr of stocks (in thousands) | 622,500 | 622,500 | 622,500 | 622,500 | 622,500 | 622,500 |
Reference price 2 | 0.8605 | 0.7864 | 0.6312 | 0.6193 | 0.7507 | 0.5726 |
Announcement Date | 4/23/19 | 4/23/20 | 4/23/21 | 4/25/22 | 4/21/23 | 4/22/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 1,079 | 977.9 | 745.4 | 847.4 | 957.7 | 1,079 |
EBITDA 1 | 90.73 | 94.24 | 91.16 | 96.46 | 107.4 | 88.52 |
EBIT 1 | 63.3 | 66.41 | 66.84 | 71.24 | 80.34 | 78.68 |
Operating Margin | 5.87% | 6.79% | 8.97% | 8.41% | 8.39% | 7.29% |
Earnings before Tax (EBT) 1 | 70.38 | 69.81 | 70.89 | 69.43 | 67.58 | 93.89 |
Net income 1 | 41 | 43.43 | 11.72 | 30.32 | 22.74 | 38.1 |
Net margin | 3.8% | 4.44% | 1.57% | 3.58% | 2.37% | 3.53% |
EPS 2 | 0.0659 | 0.0700 | 0.0191 | 0.0500 | 0.0375 | 0.0644 |
Free Cash Flow 1 | 52.63 | 111 | 107 | 10.66 | 87.37 | -64.91 |
FCF margin | 4.88% | 11.35% | 14.35% | 1.26% | 9.12% | -6.02% |
FCF Conversion (EBITDA) | 58.01% | 117.82% | 117.37% | 11.06% | 81.36% | - |
FCF Conversion (Net income) | 128.35% | 255.66% | 913.23% | 35.18% | 384.2% | - |
Dividend per Share 2 | 0.0198 | 0.0209 | 0.005500 | 0.0195 | 0.0218 | 0.0306 |
Announcement Date | 4/23/19 | 4/23/20 | 4/23/21 | 4/25/22 | 4/21/23 | 4/22/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 161 | 103 | 44.3 | 40.6 | 34.5 | 160 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 1.773 x | 1.093 x | 0.4861 x | 0.4204 x | 0.3213 x | 1.812 x |
Free Cash Flow 1 | 52.6 | 111 | 107 | 10.7 | 87.4 | -64.9 |
ROE (net income / shareholders' equity) | 8.09% | 7.67% | 7.53% | 7.32% | 6.16% | 8.84% |
ROA (Net income/ Total Assets) | 3.01% | 3.22% | 3.29% | 3.61% | 4.05% | 3.78% |
Assets 1 | 1,363 | 1,348 | 355.6 | 840.7 | 561 | 1,008 |
Book Value Per Share 2 | 0.9100 | 0.9700 | 0.9500 | 0.9900 | 0.9900 | 1.040 |
Cash Flow per Share 2 | 0.2600 | 0.1800 | 0.4000 | 0.3000 | 0.3900 | 0.2900 |
Capex 1 | 11.9 | 8.8 | 9.93 | 58.3 | 93.5 | 106 |
Capex / Sales | 1.1% | 0.9% | 1.33% | 6.88% | 9.76% | 9.78% |
Announcement Date | 4/23/19 | 4/23/20 | 4/23/21 | 4/25/22 | 4/21/23 | 4/22/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 47.82M | |
-4.75% | 23.38B | |
+5.13% | 8.58B | |
+9.21% | 8.46B | |
-20.79% | 7.94B | |
+14.16% | 5.3B | |
+12.27% | 4.14B | |
-1.41% | 4.12B | |
-1.86% | 3.87B | |
+23.24% | 3.68B |
- Stock Market
- Equities
- 1110 Stock
- Financials Kingworld Medicines Group Limited